Novavax awarded $1.6B for Covid-19 vaccine development under Operation Warp Speed July 7, 2020 Auto Bot BioPharma, biopharma nl, Maryland, Novavax, NVX-CoV2373, SARS-CoV-2, Vaccines 0 The company is running a Phase I/II study that started in May in Australia and plans to open a Phase III study of its vaccine candidate, NVX-CoV2373, that will enroll up to 30,000 participants starting in the fall.